Summary:
Alpine Clinical Research Center is conducting a research study to assess the efficacy, safety and immunogenicity of BI 695501 versus adalimumab (Humira) in patients with active rheumatoid arthritis: a randomized, 58-week, double-blind, parallel arm, multiple dose, active comparator trial.
BI 695501 is a product being developed that is similar to Humira. There is no placebo in this trial.
We are seeking adult patients, between 18 and 80 years of age, with moderately to severely active RA for at least 6 months as defined by at least six swollen joints and at least six tender joints. Patients must currently be receiving Methotrexate therapy. Prior treatment with Humira is not permitted.
Qualified Participants May Receive:
All study related medical care and physical exams at no cost, Investigation Medication and Compensation of up to $1000.00 for time and travel to necessary study visits.